STAAR Surgical Company designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems. Its implantable collamer lens (ICL) product family includes EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL, used in refractive surgery to treat visual disorders such as myopia, hyperopia, astigmatism, and presbyopia. The company serves ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, distributors, and ophthalmologists. It sells directly through sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, and through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. Incorporated in 1982, STAAR Surgical is headquartered in Lake Forest, California.
STAAR Surgical authorized a share repurchase program of up to $50M after Thursday's market close, sending shares about 7% higher in Friday trading. The buyback will be funded with organic free cash flow and cash on hand. Despite the gain, STAAR Surgical is down about 12% year to date and off about 24% over the last year.
Globus Medical Q2 Revenue Rises 5.9% to $789.6 Million, Beats Estimates
Globus Medical reported second-quarter revenues of $789.6 million, up 5.9% year on year and 0.9% above analysts' expectations, as the medical devices and supplies specialty industry posted a strong quarter overall. The company also beat analysts' full-year EPS guidance estimates and their quarterly EPS estimates, with President and Chief Executive Officer Keith Pfeil citing 6% overall revenue growth, or 9% excluding Nevro, driven by share gains in US Spine, up 7%, and International Spine, up 14% as-reported and 12% on a constant currency basis. Despite the beat, Globus Medical shares are down 8.8% since reporting and trade at $73.94. Across the seven specialty medical device stocks tracked, group revenues beat consensus by 2.1%, with Inspire Medical Systems posting the highest full-year guidance raise of the group and STAAR Surgical delivering the biggest analyst estimate beat and fastest revenue growth, while Enovis turned in the weakest performance against estimates and the weakest guidance update. Inspire Medical Systems shares are up 32.3% since reporting at $69.08, Haemonetics is up 27.8% at $106.86, STAAR Surgical is down 21.8% at $19.87, and Enovis is down 39.6% at $18.24.
GMED · Capital · Positive Globus Medical beat Q2 revenue and EPS estimates with 5.9% revenue growth and raised full-year EPS guidance.
ENOV · Capital · Negative Enovis turned in the weakest performance against estimates and the weakest guidance update among the tracked medical device stocks.
INSP · Capital · Positive Inspire Medical Systems posted the highest full-year guidance raise of the tracked medical device group.
STAA · Capital · Neutral STAAR Surgical delivered the biggest analyst estimate beat and fastest revenue growth, yet its shares are down 21.8% since reporting.
HAE · Capital · Positive Haemonetics shares are up 27.8% since reporting, cited among the strong specialty medical device group results.
STAAR Surgical Swings to Profit as China Sales More Than Double
STAAR Surgical reported second-quarter results on August 12 for the quarter ended July 3, swinging to $8.1 million of net income from a year-earlier loss as net sales jumped 111% year over year to $93.5 million. China sales more than doubled to $52.3 million, now accounting for more than half of total revenue, driven largely by the EVO+ lens variant launched earlier in the year, which lifted both procedure volumes and average selling prices as patients shifted toward pricier toric lenses. Sales outside China rose 6% to $41.2 million, with the Americas up 12% on growing US market share and EMEA excluding the Middle East also up 12%, while overall EMEA slipped 1% on continued Middle East disruption. Gross margin improved to 74.5% from 74.0%, and the company ended the quarter with $181.5 million in cash and no debt, up from $163.9 million three months earlier. Management cautioned that the 111% growth reflects an unusually weak year-earlier baseline, when STAAR shipped only minimal quantities to China as distributors worked down excess inventory, and asked investors to compare the coming third quarter against an adjusted base of $68.8 million rather than the reported $94.7 million, which included a one-time $25.9 million order. New CEO Warren Foust, who became permanent CEO after six months as interim co-CEO, is still searching for a Chief Technology Officer to lead the promised innovation push.
Intuitive Surgical warning on insurance changes hits medical device stocks
Shares of several medical device companies fell after Intuitive Surgical warned that changes to some insurance plans could slow U.S. procedure growth, sparking fears of a sector-wide slowdown. STAAR Surgical dropped 10.1%, Globus Medical fell 4.4%, Integer Holdings declined 4.1%, and Enovis lost 5.1%. The warning suggests that shifting insurance coverage could dampen the number of medical procedures performed in the United States, creating headwinds for the entire industry reliant on steady procedure volumes.
STAAR Surgical drops 10% despite Q2 sales beat as analysts flag outlook uncertainty
STAAR Surgical shares fell about 10% on Friday, potentially the worst one-day drop since February 2025, even after the company reported preliminary second-quarter net sales exceeding $90 million, above the $89.4 million analyst consensus and more than double the prior-year period. Jefferies analyst Young Li noted management did not provide second-half guidance and continued to express caution, saying investors want guidance before becoming more constructive. Needham’s David Saxon wrote that the preannouncement lowers the bar for the second half but adds ambiguity, while BTIG’s Ryan Zimmerman cited similar concerns, pointing to seasonality in the Chinese market as a key overhang and the lack of full-year revenue guidance.
STAA · Capital · Negative Company reported Q2 sales beat but management did not provide second-half guidance, causing analyst uncertainty and a 10% stock drop.
Netflix, SpaceX lead Friday's biggest stock declines
Stock futures edged lower early Friday as a major correction in the semiconductor space overshadowed a supportive domestic inflation backdrop. Netflix shares plunged 10% after the streaming giant reported mixed second-quarter results, with revenue narrowly missing expectations and full-year revenue guidance of 51.0 billion to 51.4 billion dollars coming in below the 51.4 billion dollar consensus. SpaceX fell 5% after an automatic launch abort of its upgraded Starship V3 rocket extended a five-day losing streak that pushed shares further below their 135 dollar IPO price. STAAR Surgical tumbled 12% despite preliminary second-quarter revenue of more than 90 million dollars roughly doubling year-over-year, as investors focused on geopolitical headwinds and operational challenges from an ERP system implementation. Intuitive Surgical slipped 9% even after beating earnings and revenue expectations, as the company maintained its full-year da Vinci procedure growth outlook of 13.5% to 15.5% and flagged tariff-related margin pressure.
StockStory analysts recommend avoiding STAAR Surgical despite its recent 16.2% gain to $27.81, citing three concerns. The company's revenue has declined at an annualized rate of 5.7% over the past two years, its free cash flow margin has dropped by 26.6 percentage points over five years to negative 18.9%, and its return on invested capital has significantly decreased, signaling limited profitable growth opportunities. With the stock trading at 37 times forward earnings, the analysts believe better opportunities exist elsewhere.
IonQ Highlighted as Cash-Heavy Stock to Watch, Columbia Sportswear and STAAR Surgical Flagged as Sells
StockStory identifies IonQ as a cash-heavy stock to watch, citing its $2.00 billion net cash position, 172% annual revenue growth over two years, and projected 53.2% revenue growth for the next 12 months. In contrast, Columbia Sportswear and STAAR Surgical are flagged as stocks to sell. Columbia Sportswear holds a net cash position of $62.79 million but struggles with 5.8% annual revenue growth over five years and a weak free cash flow margin of 6.9%. STAAR Surgical has a net cash position of $94.57 million but faces a 5.7% annual revenue decline over two years and a 26.6 percentage point drop in free cash flow margin over five years.
Healthcare Equipment and Supplies Stocks Post Mixed Q1 Results
Healthcare equipment and supplies stocks reported mixed first-quarter results, with the 37 companies tracked collectively beating revenue estimates by 2.3% but issuing next-quarter guidance 1.3% below expectations. Lantheus posted revenues of $377.3 million, up 1.2% year on year and exceeding estimates by 6.4%, though its full-year revenue guidance missed. STAAR Surgical delivered the strongest performance, with revenues surging 120% to $93.52 million and beating estimates by 20.8%, while Stryker was the weakest, reporting $6.02 billion in revenue that fell 5% short of expectations. Abbott Laboratories reported $11.16 billion in revenue, up 7.8% and beating estimates by 1.3%, and Integra LifeSciences posted $391.9 million, up 2.4% and exceeding estimates by 2.6%. On average, share prices across the group have declined 1.4% since the latest earnings results.
GE HealthCare Q1 revenue beats but full-year EPS guidance disappoints
GE HealthCare reported first-quarter revenues of $5.13 billion, up 7.4% year on year and exceeding analyst expectations by 2.1%, but the company significantly missed full-year EPS guidance and quarterly EPS estimates. The stock fell 11.1% since the report and now trades at $60.91. Among the 37 healthcare equipment and supplies stocks tracked, aggregate revenues beat consensus by 2.3% while next-quarter revenue guidance came in 1.3% below estimates. STAAR Surgical posted the strongest performance with revenues of $93.52 million, up 120% year on year and beating estimates by 20.8%, while Stryker was the weakest with revenues of $6.02 billion, up 2.6% but missing expectations by 5%.
StockStory Flags Richardson Electronics and STAAR Surgical as Risky Cash Burners, Highlights Kratos as a Stock to Watch
StockStory identifies Richardson Electronics and STAAR Surgical as risky cash-burning stocks to sell, while naming Kratos as a high-risk, high-reward stock to watch. Richardson Electronics, trading at $18.10 per share with a forward P/E of 47.8x, posted a trailing 12-month free cash flow margin of negative 2.6% and annual revenue growth of just 1.5% over the last two years. STAAR Surgical, at $29.12 per share and 38.4x forward P/E, saw its free cash flow margin shrink by 26.6 percentage points over five years to negative 18.9%, alongside annual sales declines of 5.7%. In contrast, Kratos, priced at $54.01 per share with a 71.3x forward P/E, achieved average organic revenue growth of 14.6% over two years and is projected to grow revenue by 29.9% in the next 12 months, with earnings per share rising 15.8% annually.
KTOS · Capital · Positive StockStory highlights Kratos as a high-risk, high-reward stock to watch with strong organic revenue growth and projected growth.
RELL · Capital · Negative StockStory flags Richardson Electronics as a risky cash-burning stock to sell due to negative free cash flow margin and low revenue growth.
STAA · Capital · Negative StockStory flags STAAR Surgical as a risky cash-burning stock to sell due to shrinking free cash flow margin and declining sales.
United States